Neervannan Seshadri

Chief Operating Officer

Neervannan Seshadri has filed 6 SEC Form 4 filings (9 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Sep 9, 2026.

On the most recent filing, Neervannan Seshadri is listed as Chief Operating Officer at Tarsus Pharmaceuticals, Inc. Inside the rolling window, Neervannan Seshadri reported no open-market purchases and 6 open-market sales totaling $2.0M in TARS. The largest disclosed transaction in the window is a sale of 8,366 TARS shares on Mar 4, 2026, worth $641K.

Companies traded

Other insiders at TARS

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$2.0M

reported sales (SEC code S)

Companies

1

in the rolling window

Source
TARSSale$388KSep 9SEC ↗
TARSSale$200KMar 24SEC ↗
TARSSale$217KMar 19SEC ↗
TARSSale$248KMar 19SEC ↗
TARSSale$307KMar 19SEC ↗
TARSSale$641KMar 5SEC ↗
Showing 1–6 of 6
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Neervannan Seshadri made?

Neervannan Seshadri has filed 6 SEC Form 4 filings (9 transaction rows) across 1 company since 2025.

Which companies does Neervannan Seshadri trade?

Neervannan Seshadri has filed SEC Form 4 disclosures for 1 company, including TARS.

When was Neervannan Seshadri's most recent SEC Form 4 filing?

Neervannan Seshadri's most recent SEC Form 4 filing on Tracefour is dated Sep 9, 2026.

What is Neervannan Seshadri's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Neervannan Seshadri is listed as Chief Operating Officer.

What is Neervannan Seshadri's total buy and sell value in the current window?

Inside the rolling retention window, Neervannan Seshadri bought $0 and sold $2.0M based on SEC Form 4 filings.

What was Neervannan Seshadri's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 8,366 TARS shares on 2026-03-04, worth $641K, per SEC Form 4 filings.